<p>Palatin (PTN) 发布了其第一季度财报。以下是 Palatin 向投资者展示的信息摘要。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的洞察。</li>
</ul>
<p>Palatin Technologies, Inc. 是一家生物制药公司，专注于开发首创药物，以调节黑色素皮质素受体系统的活性，针对具有显著未满足医疗需求的疾病。在其最新的财报中，Palatin 强调了其肥胖治疗管线的重大进展、战略合作以及财务表现。该公司正在推进其基于黑色素皮质素的肥胖治疗，包括预计在 2026 年初进入临床试验的口服小分子 PL7737。此外，Palatin 通过成功的 1820 万美元公开募股和与博瑞医药的合作，进一步增强了其财务状况，这已带来了预付款和里程碑付款。2026 财年第一季度的关键财务指标包括合作和许可收入显著增加至 880 万美元，运营费用减少至 420 万美元，净收入为 470 万美元，标志着与去年亏损相比的显著扭转。展望未来，Palatin 凭借强大的管线和战略合作伙伴关系，准备继续增长，旨在创造长期价值并解决肥胖治疗及其他领域的未满足医疗需求。</p>

Palatin技术

<p>Palatin 技术公司发布 2026 年第一季度强劲业绩报告</p>

<p>Palatin ( (PTN) ) has released its Q1 earnings. Here is a breakdown of the information Palatin presented to its investors.</p>
<div class="lb-trans"><p>Palatin (PTN) 发布了其第一季度财报。以下是 Palatin 向投资者展示的信息摘要。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的洞察。</li>
</ul>
</div><p>Palatin Technologies, Inc., a biopharmaceutical company, is focused on developing first-in-class medicines that modulate the activity of the melanocortin receptor system, targeting diseases with significant unmet medical needs. In its latest earnings report, Palatin highlighted significant advancements in its obesity treatment pipeline, strategic collaborations, and financial performance. The company is progressing with its melanocortin-based therapies for obesity, including the oral small molecule PL7737, which is expected to enter clinical trials in early 2026. Additionally, Palatin has strengthened its financial position through a successful $18.2 million public offering and a collaboration with Boehringer Ingelheim, which has already resulted in upfront and milestone payments. Key financial metrics for the first quarter of fiscal year 2026 include a notable increase in collaboration and license revenue to $8.8 million, a reduction in operating expenses to $4.2 million, and a net income of $4.7 million, marking a significant turnaround from the previous year’s loss. Looking ahead, Palatin is poised for continued growth with a robust pipeline and strategic partnerships, aiming to create long-term value and address unmet medical needs in obesity treatment and other areas.</p>
<div class="lb-trans"><p>Palatin Technologies, Inc. 是一家生物制药公司，专注于开发首创药物，以调节黑色素皮质素受体系统的活性，针对具有显著未满足医疗需求的疾病。在其最新的财报中，Palatin 强调了其肥胖治疗管线的重大进展、战略合作以及财务表现。该公司正在推进其基于黑色素皮质素的肥胖治疗，包括预计在 2026 年初进入临床试验的口服小分子 PL7737。此外，Palatin 通过成功的 1820 万美元公开募股和与博瑞医药的合作，进一步增强了其财务状况，这已带来了预付款和里程碑付款。2026 财年第一季度的关键财务指标包括合作和许可收入显著增加至 880 万美元，运营费用减少至 420 万美元，净收入为 470 万美元，标志着与去年亏损相比的显著扭转。展望未来，Palatin 凭借强大的管线和战略合作伙伴关系，准备继续增长，旨在创造长期价值并解决肥胖治疗及其他领域的未满足医疗需求。</p>
</div>

Palatin Technologies 报告 2026 年第一季度业绩强劲